← All trials
NCT00006400
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2000
- Primary completion
- Sep 1, 2009
- Completion date
- Sep 1, 2009
- First posted
- —
- Last posted
- —
- Enrollment
- 191
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- National Heart, Lung, and Blood Institute (NHLBI)Lead sponsor
- Johns Hopkins UniversityOverall official - principal investigator
- Howard UniversityOverall official - principal investigator
- Duke UniversityOverall official - principal investigator
- Drexel UniversityOverall official - principal investigator
- Emory UniversityOverall official - principal investigator
- Wayne State UniversityOverall official - principal investigator
- Children's National Medical CenterOverall official - principal investigator
- Medical University of South CarolinaOverall official - principal investigator
- Clinical Trials and Surveys CorpOverall official - principal investigator
- University of MiamiOverall official - principal investigator
- State University of New York, BrooklynOverall official - principal investigator
- St. Jude Children's HospitalStudy chair
- University of Alabama, BirminghamOverall official - principal investigator
- University of MississippiOverall official - principal investigator
- The University of Texas, DallasOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.